The AUC of selumetinib, a mitogen-activated protein kinase 1 and 2 (MEK1/2) inhibitor approved by the FDA for the treatment of tumors associated with neurofibromatosis [30], had the highest negative correlation with the expression of TMSB10 (Fig. 8A). Here, MAPK1 is linked to neurofibromatosis.